CD93 and neoplasm: Recent work detailing blockade with a CD93 mAb has led to interesting and promising results toward tumor vessel normalization rather than depletion as seen in antibody-directed binding to other group XIV CTLDs such as CD248 and CLEC14a as will be discussed in subsequent sections (Fig. 2a).